|
|
| | CDK4/6-IN-2 Basic information |
| Product Name: | CDK4/6-IN-2 | | Synonyms: | CDK4/6-IN-2;CDK4/6 inhibitor 2;5-((4-ethylpiperazin-1-yl)methyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyridin-2-yl)pyrimidin-2-amine;AM24679P4;Cyclin dependent kinase,CDK-4/6-IN-2,CDK,CDK4/6 IN 2,CDK4/6IN2,inhibit,Inhibitor;2-Pyrimidinamine, 5-[(4-ethyl-1-piperazinyl)methyl]-N-[5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyridinyl]-;Bireociclib (XZP-3287,CDK4/6-IN-2 ) | | CAS: | 1800506-48-2 | | MF: | C27H32F2N8 | | MW: | 506.59 | | EINECS: | | | Product Categories: | | | Mol File: | 1800506-48-2.mol |  |
| | CDK4/6-IN-2 Chemical Properties |
| Boiling point | 665.2±65.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 5.2 mg/mL (10.26 mM) | | pka | 7.67±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | CDK4/6-IN-2 Usage And Synthesis |
| Description | CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC50s of 2.7 and 16 nM for CDK4 and CDK6, respectively[1].
CDK4|2.7 nM (IC50)|CDK6|16 nM (IC50)
CDK4/6-IN-2 inhibits H358, H441, PC3, MV-4-11, JeKo-1, SW780, and HGC-27 cells with IC50s of 290.9, 147.8, 260.5, 139, 36.98, 162.5, and 316.4 nM, respectively[1]. | | Uses | CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC50s of 2.7 and 16 nM for CDK4 and CDK6, respectively[1]. | | IC 50 | CDK4: 2.7 nM (IC50); CDK6: 16 nM (IC50) | | References | [1]. Frank Wu, et al. Kinase inhibitor and use thereof. US20180000819A1. |
| | CDK4/6-IN-2 Preparation Products And Raw materials |
|